Results are presented of enrolling HIV+ active-injection drug users (IDUs) into a peer-driven intervention (PDI) to improve their adherence to medical care. Using respondent-driven sampling (RDS), which evolved out of the PDI model, the authors recruited and tested 1,097 IDUs, of whom 145 were confirmed to be HIV+. Despite promises of confidentiality, increased social supports, and direct cash rewards for participating, only 78 (54%) of the HIV+ IDUs enrolled in the subsequent adherence study. Correlates of participation as well as interviews with respondents who declined participating are presented. The seemingly negative findings have important implications for future adherence studies. RDS provided a powerful mechanism for recruiting HIV+ IDUs. But selection biases were revealed to favor sicker yet more socially connected respondents, which resulted in more conservative outcomes with regard to social supports and positive health-seeking behaviors. The analysis may help streamline future efforts using the PDI, which harnesses IDUs’ abilities to help one another, by underscoring some of the mechanism’s limitations.
AlticeF. L.MezgerJ. A.HodgesJ.BruceR. D.MarinovichA.WaltonM.. . . FriedlandG. H. (2004). Developing a directly administered antiretroviral therapy intervention for HIV-infected drug users: Implications for program replication. Clinical Infectious Diseases, 38(Suppl. 5), S376-S387.
2.
AndersonL. A.DedrickR. F. (1990). Development of the trust in physician scale: A measure to assess interpersonal trust in patient-physician relationships. Psychological Reports, 67(3, Pt. 2), 1091-1100.
3.
BangsbergD. R. (2006). Less than 95% adherence to nonnucleoside reverse-transcriptase inhibitor therapy can lead to viral suppression. Clinical Infectious Diseases, 43, 939-941.
4.
BourdieuP. (1985). The forms of capital. In RichardsonJ. G. (Ed.), Handbook of theory and research on education (pp. 241-258). New York, NY: Greenwood.
5.
BourgoisP.SchonbergJ. (2009). Righteous dopefiend. Berkeley: University of California Press.
6.
BroadheadR. S.HammettT. M.KlingR.NguD.LiuW.ChenY.. . . Des JarlaisD. C. (2009). Peer-driven interventions in Vietnam and China to prevent HIV: A pilot study targeting injection drug users. Journal of Drug Issues, 39(Fall), 830-850.
7.
BroadheadR. S.HeckathornD. D. (1994). AIDS prevention outreach among injection drug users: Agency problems and new approaches. Social Problems, 41, 473-495.
8.
BroadheadR. S.HeckathornD. D.AlticeF. L.van HulstY.CarboneM.FriedlandG. H.. . . SelwynP. A. (2002). Increasing drug users’ adherence to HIV treatment: Results of a peer-driven intervention feasibility study. Social Science & Medicine, 55, 235-246.
9.
BroadheadR. S.HeckathornD. D.WeakliemD. L.AnthonyD. L.MadrayH.MillsR. J.HughesJ. J. (1998). Harnessing peer networks as an instrument for AIDS prevention: Results from a peer-driven intervention. Public Health Reports, 113(Suppl. 1), 42-57.
10.
BroadheadR. S.KerrT. H.GrundJ.-P.AlticeF. L. (2002). Safer injection facilities in North America: Their place in public policy and health initiatives. Journal of Drug Issues, 32(Winter), 329-355.
11.
BroadheadR. S.VolkanevskyV. L.RydanovaT.RyabkovaM.BorchC.van HulstY.. . . HeckathornD. D. (2006). Peer-driven HIV interventions for drug injectors in Russia: First year impact results of a field experiment. International Journal of Drug Policy, 17, 379-392.
12.
BuxD. A.IguchiM.LidzV. Y.BaxterR. C.PlattJ. J. (1993). Participation in an outreach-based coupon distribution program for free methadone detoxification. Hospital and Community Pharmacy, 44, 1066-1072.
13.
ColemanJ. S. (1988). Social capital in the creation of human capital. American Journal of Sociology, 94, S95-S120.
14.
DeciE. L.RyanR. M. (1985). Intrinsic motivation and self-determination in human behavior. New York, NY: Plenum Press.
15.
DeeksS. G. (2003). Treatment of antiretroviral-drug-resistant HIV-1 infection. Lancet, 362, 2002-2011.
16.
FrankR. (1988). Passions within reason. New York, NY: Norton.
17.
FrenchR.PowerR.MitchellS. (2000). An evaluation of peer-led STD/HIV prevention work in a public sex environment. AIDS Care, 12, 225-234.
18.
GeboK. A.KerulyJ.MooreR. D. (2003). Association of social stress, illicit drug use, and health beliefs with nonadherence to antiretroviral therapy. Journal of General Internal Medicine, 18, 104-111.
19.
GrossR.YipB.Lo ReV.3rdWoodE.AlexanderC. S.HarriganP. R.. . . HoggR. S. (2006). A simple, dynamic measure of antiretroviral therapy adherence predicts failure to maintain HIV-1 suppression. Journal of Infectious Diseases, 194, 1108-1114.
20.
HaverkosH. W. (1991). Infectious diseases and drug abuse: Prevention and treatment in the drug abuse treatment system. Journal of Substance Abuse Treatment, 8, 269-275.
21.
HaysR. B.RebchookG. M.KegelesS. M. (2003). The empowerment project: Community-building with young gay and bisexual men to prevent HIV1. American Journal of Community Psychology, 31, 301-312.
22.
HeckathornD. D. (1990). Collective sanctions and compliance norms: A formal theory of group-mediated social control. American Sociological Review, 55, 366-384.
23.
HeckathornD. D. (2002). Respondent-driven sampling II: Deriving valid populations estimates from chain-referral samples of hidden populations. Social Problems, 49, 11-34.
24.
HeckathornD. D.BroadheadR. S. (1996). Rational choice, public policy and AIDS. Rationality and Society, 8, 235-260.
25.
HeckathornD. D.SemaanS.BroadheadR. S.HughesJ. J. (2002). Extensions of respondent-driven sampling: A new approach to the study of injection drug users aged 18-25. AIDS and Behavior, 6, 55-67.
26.
InciardiJ.HarrisonL. D. (2000). Harm reduction: National and international perspectives. Thousand Oaks, CA: SAGE.
27.
KatzM. H. D.CunninghamW. E.FleishmanJ. A.AndersenR. M.KelloggT.BozzetteS. A.ShapiroM. F. (2001). Effect of case management on unmet needs and utilization of medical care and medications among HIV-infected persons. Annals of Internal Medicine, 135(8, Pt. 1), 557-565.
28.
KegelesS. M.HaysR. B.PollackL. M.CoatesT. J. (1999). Mobilizing young gay and bisexual men for HIV prevention: A two-community study. AIDS, 13, 1753-1762.
29.
KellyJ. A. (2004). Popular opinion leaders and HIV prevention peer education: Resolving discrepant findings, and implications for the development of effective community programmes. AIDS Care, 16, 139-150.
30.
KellyJ. A.St. LawrenceJ. S.StevensonL. Y.HauthA. C.KalichmanS. C.DiazY. E.. . . MorganM. G. (1992). Community AIDS/HIV risk reduction: The effects of endorsements by popular people in three cities. American Journal of Public Health, 82, 1483-1489.
31.
KerrT.MarshallA.WalshJ.PalepuA.TyndallM.MontanerJ.. . . WoodE. (2005). Determinants of HAART discontinuation among injection drug users. AIDS Care, 17, 539-549.
32.
KrüsiA.WoodE.MontanerJ.KerrT. (2010). Social and structural determinants of HAART access and adherence among injection drug users. International Journal of Drug Policy, 21, 4-9.
33.
LatkinC. A.HuaW.DaveyM. A. (2004). Factors associated with peer HIV prevention outreach in drug-using communities. AIDS Education and Prevention, 16, 499-508.
34.
LatkinC. A.ShermanS.KnowltonA. (2003). HIV prevention among drug users: Outcome of a network-oriented peer outreach intervention. Health Psychology, 22, 332-339.
35.
LeviP. (1988). The drowned and the saved. New York, NY: Summit Books.
36.
LucasG. M.GriswoldM.GeboK. A.KerulyJ.ChaissonR. E.MooreR. D. (2006). Illicit drug use and HIV-1 disease progression: A longitudinal study in the era of highly active antiretroviral therapy. American Journal of Epidemiology, 163, 412-420.
37.
MolitorF.KuennethC.WaltermeyerJ.MendozaM.AguirreA.BrockmannK.CrumpC. (2005). Linking HIV-infected persons of color and injection drug users to HIV medical and other services: The California Bridge Project. AIDS Patient Care and STDs, 19, 406-412.
38.
O’ConnorP. G.MoldeS.HenryS.ShockcorW. T.SchottenfeldR. S. (1992). Human immunodeficiency virus infection in intravenous drug users: A model for primary care. American Journal of Medicine, 93, 382-386.
39.
OstertagS.WrightB. R. E.BroadheadR. S.AlticeF. L. (2006). Trust and other characteristics associated with health care utilization by injection drug users. Journal of Drug Issues, 36, 953-974.
40.
OstromE. (1990). Governing the commons: The evolution of institutions for collective action. New York, NY: Cambridge University Press.
41.
PurcellD. W.LatkaM. H.MetschL. R.LatkinC. A.GómezC. A.MizunoY.. . . BorkowfC. B. (2007). Results from a randomized controlled trial of a peer-mentoring intervention to reduce HIV transmission and increase access to care and adherence to HIV medications among HIV-seropositive injection drug users. Journal of Acquired Immune Deficiency Syndromes, 46(Suppl. 2), S35-S47.
42.
PurcellD. W.MetschL. R.LisaR.LatkaM. H.SantibanezS.GómezC. A.. . . LatkinC. A. (2004). Interventions for seropositive injectors-research and evaluation: An integrated behavioral intervention with HIV-positive injection drug users to address medical care, adherence, and risk reduction. Journal of Acquired Immune Deficiency Syndromes, 37(Suppl. 20), S110-S118.
43.
Rodriguez-ArenasM. A.JarrinI.Del AmoJ.IribarrenJ. A.MorenoS.VicianaP.. . . HoyosS. P. (2006). Delay in the initiation of HAART, poorer virological response, and higher mortality among HIV-infected injecting drug users in Spain. AIDS Research and Human Retroviruses, 22, 715-723.
44.
SelwynP. A.BatkiS. L. (1995). Treatment for HIV-infected alcohol and other drug abusers (Treatment Improvement Protocol, Series 15). Rockville, MD: United States Public Health Service.
45.
SemaanS.FlemingP.WorrellC.StolpH.BaackB.MillerM. (2011). Potential role of safer injection facilities in reducing HIV and hepatitis C infections and overdose mortality in the United States. Drug and Alcohol Dependence, 118, 100-110.
46.
SikkemaK. J.AndersonE. S.KellyJ. E.WinettR. A.Gore-FeltonC.RoffmanR. A.. . . BrondinoM. J. (2005). Outcomes of a randomized, controlled community-level HIV prevention intervention for adolescents in low-income housing developments. AIDS, 19, 1509-1516.
47.
Umbricht-SchneiterA.GinnD. H.PabstK. M.BigelowG. E. (1994). Providing medical care to methadone clinic patients: Referral vs. on-site care. American Journal of Public Health, 84, 207-210.
48.
WareJ. E. (1997). SF-36 Health Survey—Quality of Life.
49.
WeeksM. R.LiJ.Dickson-GomezJ.ConveyM.MartinezM.RaddaK.ClairS. (2009). Outcomes of a peer HIV prevention program with injection drug and crack users: The risk avoidance partnership. Substance Use and Misuse, 44, 253-281.
50.
WoodE.KerrT.HoggR. S.PalepuA.ZhangR.StrathdeeS. A.MontanerJ. S. G. (2006). Impact of HIV testing on uptake of HIV therapy among antiretroviral naive HIV-infected injection drug users. Drug Alcohol Review, 25, 451-454.
51.
WoodE.KerrT.SmallW.TyndallM. W.O’ShaughnessyM. V.SchechterM. T. (2003). An external evaluation of a peer-run unsanctioned syringe exchange program. Journal of Urban Health, 80, 455-464.
52.
WoodE.KerrT.TyndallM. W.MontanerJ. S. G. (2008). A review of barriers and facilitators of HIV treatment among injection drug users. AIDS, 22, 1247-1256.
53.
WoodE.MontanerJ. S.YipB.TyndallM. W.SchechterM. T.O’ShaughnessyM. V.HoggR. S. (2004). Adherence to antiretroviral therapy and CD4 T-cell count responses among HIV-infected injection drug users. Antiviral Therapy, 9, 229-235.
